ANTI-INFLAMMATORY DRUGS MARKET ANALYSIS

Anti-inflammatory Drugs Market, By Drug Type (Nonsteroidal Anti-inflammatory Drugs (NSAlDs), Immune Selective Anti-inflammatory Derivatives (ImSAlDs), Anti-inflammatory Biologics, Corticosteroids), By Application (Arthritis, Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, Inflammatory Bowel Disease (IBD), Gout, Others), By Route of Administration (Oral, Topical, Injection, Inhalation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Jul 2024
Code : CMI4327
Pages :200
Formats :
Excel and PDF
Industry : Pharmaceutical

Key Developments

In April 2024, Glenmark Pharmaceuticals, a pharmaceutical company, announced that it had received FDA approval to sell a generic version of the anti-inflammatory drug Acetaminophen and Ibuprofen tablets (250 mg/125 mg) in the U.S. This product is the generic equivalent of Haleon US Holdings, LLC's Advil 2 Dual Action with Acetaminophen Tablets, 250 mg/125 mg (OTC).
In March 2024, Endo International plc, a pharmaceutical company, launched ibuprofen-famotidine 800 mg/26.6 mg tablets through its subsidiary- Par Pharmaceutical, Inc. This generic version of Amgen's DUEXIS aims to offer healthcare providers and patients more affordable treatment options for relieving the signs and symptoms of rheumatoid arthritis and osteoarthritis.
In February 2024, Hikma Pharmaceuticals PLC launched COMBOGESIC IV in the U.S., an intravenous medication combining acetaminophen (1,000 mg) and ibuprofen (300 mg). Approved by the U.S. FDA in October 2023, it provides opioid-free pain relief for adults. This formulation is intended for situations requiring intravenous administration, such as mild to moderate pain relief and management of moderate to severe pain, often used adjunctively with opioid analgesics as clinically necessary.
On May 18, 2023, AbbVie, Inc. announced that the U.S. Food and Drug Administration (FDA) had approved RINVOQ (upadacitinib) for treating adults with moderately to severely active Crohn's disease who have shown inadequate response or intolerance to one or more TNF blockers
On March 11, 2022, Pfizer, Inc. announced the successful acquisition of Arena Pharmaceuticals, a clinical-stage company focused on developing novel therapies for various immuno-inflammatory diseases